Daniel Egle - Gynecology

Author Information

Daniel Egle is affiliated with the Department of Gynecology and Gynecological Oncology at the Medical University of Innsbruck, Innsbruck, Austria. His work is primarily focused on the field of breast cancer, particularly in understanding the dynamics of treatment responses and the impact of various therapeutic strategies on patient outcomes.

Research Contributions

Daniel Egle has made significant contributions to the field of breast cancer research, particularly in the context of triple negative breast cancer (TNBC) and early-stage breast cancer. His recent works include studies on the effectiveness of different treatment regimens, the role of immunotherapy, and the impact of concomitant treatments such as statins. His research often involves large clinical trials and retrospective analyses, contributing valuable insights into the management of breast cancer.

Aliases

The author is also known by several aliases, including D Egle, D L Egle, and D. Egle.

Publication and Citation Metrics

Metric	Value
Total Papers	137
Total Citations	3568
h-index	25

Publications:

Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial

DOI: 10.1158/1538-7445.sabcs21-p2-07-12

Year: 2022

Abstract GS1-00: Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial

DOI: 10.1158/1538-7445.sabcs21-gs1-00

Year: 2022

A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort

DOI: 10.1016/j.breast.2022.02.010

Year: 2022

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.

DOI: 10.1016/j.annonc.2022.02.004

Year: 2022

Abstract P5-18-02: Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer

DOI: 10.1158/1538-7445.sabcs21-p5-18-02

Year: 2022

Abstract P1-16-03: Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry

DOI: 10.1158/1538-7445.sabcs21-p1-16-03

Year: 2022

Abstract P1-04-02: Immune milieu associated with PD-L1 status in TNBC is dependent on time of biomarker assessment and treatment received: A secondary analysis of the NeoTRIPaPDL1 trial

DOI: 10.1158/1538-7445.sabcs21-p1-04-02

Year: 2022

Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18.

DOI: 10.1016/j.esmoop.2022.100426

Year: 2022

Abstract P1-15-01: Effect of concomitant statin treatment in postmenopausal patients with hormone-receptor positive early-stage breast cancer receiving adjuvant denosumab or placebo: A post-hoc analysis of ABCSG-18

DOI: 10.1158/1538-7445.sabcs21-p1-15-01

Year: 2022

Abstract P4-12-01: Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial

DOI: 10.1158/1538-7445.sabcs21-p4-12-01

Year: 2022

Can Tubal Blockage be Treated?

Can You Bring Someone with You?

How to Improve Cash Flow?

Are there any risks associated with magnesium supplements?

What Role Do Hormones Play in Individual Variability?

What are the Common Oral Health Issues During Pregnancy?

Are There Medications for Managing Blood Pressure?

When is Chadwick's Sign Observed?

How Do Hands-Free Pumping Bras Work?

What Are Tumor Antigens?

Partnered Content Networks

Relevant Topics